Investigational Testing of Bodycad Unicompartmental Knee Prosthesis (UKS)

Osteoarthritis, Knee Clinical Trial

Official title:

Open-Label Investigational Testing of Bodycad Unicompartmental Knee Prosthesis (UKS) in Human Subjects With Medial Unicompartmental Knee Osteoarthritis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03432481
• Other study ID #: PRO-PB001-42
• Status: Terminated
• Phase: N/A
• Start date: January 24, 2018
• Est. completion date: March 7, 2023

Study information

• Verified date: August 2023
• Source: Laboratoires Bodycad Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to observe clinical outcomes of patient-specific knee arthroplasty in patients with osteoarthritis of the medial condyle.

Description:

The patient-specific Bodycad Unicompartmental Knee System will be implanted on patients with knee osteoarthritis of the medial condyle. The study's hypothesis is that personalized shape and fit of patient-specific knee replacement prosthesis will provide a greater stability and a more natural knee motion in addition to a faster recovery when compared to traditional knee replacement systems. This study is designed to provide a five-years follow-up clinical data on safety and effectiveness of the device.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 28
• Est. completion date: March 7, 2023
• Est. primary completion date: August 20, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 45 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Medial unicompartmental knee osteoarthritic disease diagnosed on the basis of the American College of Rheumatology criterion with radiographic confirmation (Kellgren- Lawrence grade 3 or higher, on a scale of 0 to 4, with higher numbers indicating more severe signs of osteoarthritis); or isolated medial compartment post-traumatic arthritis supported by long film (x-ray);

2. Between the ages of at least 45 years and 70 years (inclusive) at the time of enrollment;

3. Stable health as judged by the Investigator;

4. Willingness to adhere to the protocol requirements as evidenced by the informed consent form duly read, signed and dated by the subject.

Exclusion Criteria:

1. Presence of active or latent infection in the knee;

2. Diagnosis of rheumatoid arthritis or avascular necrosis;

3. Presence of moderate patellofemoral osteoarthritic disease or patellofemoral maltracking;

4. Anterior or posterior translational, varus or valgus ligamentous knee instability and/or deformity;

5. Extension deficit > 15° of affected knee;

6. History of ligament surgery on the affected knee, patient that already have a prosthesis on other condyles of the affected knee and/or patient requiring a revision knee replacement surgery;

7. History of proximal tibial fracture, non-union, deformity or oblique joint line;

8. Deficient bone mass that may not provide adequate support and / or fixation;

9. Skeletal immaturity;

10. Obesity: BMI above 35

11. Risk of exposing the prosthesis to overload by the practice of contact or high impact sports such as: baseball, hockey, basketball, football, soccer, karate, skiing etc;

12. Known sensitivity to CoCrMo, Titanium, and polyethylene components of the UKS Prosthesis used in the manufacturing of the prosthesis;

13. Pre-existing medical conditions such as history of cancer other than skin cancer, poorly controlled diabetes, systemic infections, immunocompromised, fibromyalgia or other general body pain conditions, which, in the opinion of the Investigator, interfere with the conduct of the study;

14. Neuromuscular condition that could lead to an unacceptable risk of instability of the prosthesis or other postoperative complications;

15. Subjects, in the opinion of the Investigator, who are unlikely to comply with the protocol (e.g. active alcoholism, drug dependency or psychotic state, unable or unwilling to adhere to study visit schedule);

16. Pregnant or nursing female subjects; or female subjects planning on becoming pregnant within the next 60 months from enrollment;

17. Subjects under guardianship, hospitalized in a public or private institution, for a reason other than research, or subject deprived of freedom;

18. Participation in an active stage of any drug, intervention or treatment trial within 30 days of enrollment.

Related Conditions & MeSH terms

• Osteoarthritis
• Osteoarthritis, Knee

Intervention

Procedure:
• Unicompartmental Knee Arthroplasty Surgery
Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS)

Device:
• Bodycad Unicompartmental Knee System (BUKS)
Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS)

Locations

Country	Name	City	State
Canada	CHU de Quebec - Universite Laval	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Laboratoires Bodycad Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in Knee Society Score (KSS) Objective	Assessment of improvement of clinical outcomes following BUKS implantation using the KSS questionnaire, to evaluate the clinical performance of the articulation	Baseline, post-operative months 3, 6, 12, 24, 36, 48 and 60
Primary	Change from baseline in Knee Osteoarthritis Outcome Score (KOOS)	Assessment of improvement of activity levels following BUKS implantation surgery using the KOOS questionnaire	Baseline, post-operative months 3, 6, 12, 24, 36, 48 and 60
Secondary	Change from baseline in mechanical axis measurement.	Determine by radiographic analysis Varus or Valgus, expected value are +/- 3 degrees	Baseline and post operative week 1
Secondary	Change from baseline of implant position fixation	The anteroposterior and medial lateral slop will be evaluated according to initial planed position. The measured angles will be compared with initial planning. The expected values are +/- 1.5 degree.	Post operative week 6, months 6, 12, 24, 36, 48 and 60
Secondary	Change from baseline on bone loss and cementation	Those measurements will be done on x-ray of the patient joint following Knee Society Radiological evaluation form.The tibial component acceptable score for this device will be 2.5 mm. The femoral component acceptable score for this device will be 6 mm.	Post operative week 6, months 6, 12, 24, 36, 48 and 60